We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$321M
Cap. Flow
-$140M
Cap. Flow %
-5.5%
Top 10 Hldgs %
33.9%
Holding
112
New
21
Increased
26
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$105M
2
DBVT
DBV Technologies
DBVT
+$41.9M
3
LCI
Lannett Company, Inc.
LCI
+$30.8M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$28.7M
5
ELV icon
Elevance Health
ELV
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$79.5M
2
MCK icon
McKesson
MCK
+$49.5M
3
NXTM
NxStage Medical Inc.
NXTM
+$43.6M
4
VTRS icon
Viatris
VTRS
+$24.8M
5
PDCO
Patterson Companies, Inc.
PDCO
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 78.77%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$130M 5.12%
5,766,000
+3,905,863
+210% +$105M
VTRS icon
2
Viatris
VTRS
$20.1B
$106M 4.17%
2,503,611
-650,000
-21% -$24.8M
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$92.6M 3.64%
6,341,894
-575,176
-8% -$8.08M
DXCM icon
4
DexCom
DXCM
$29.6B
$88M 3.47%
6,136,844
+457,200
+8% +$5.94M
GKOS icon
5
Glaukos
GKOS
$9.21B
$85.7M 3.37%
3,343,045
+816,013
+32% +$24.3M
AVXS
6
DELISTED
AveXis, Inc. Common Stock
AVXS
$83.6M 3.29%
755,798
-791,588
-51% -$79.5M
ANAB icon
7
AnaptysBio
ANAB
$1.72B
$81.8M 3.22%
812,484
-11,854
-1% -$873K
LCI
8
DELISTED
Lannett Company, Inc.
LCI
$63M 2.48%
679,322
+316,007
+87% +$30.8M
MCK icon
9
McKesson
MCK
$98.5B
$61.6M 2.42%
394,801
-334,199
-46% -$49.5M
ACRS icon
10
Aclaris Therapeutics
ACRS
$793M
$55.1M 2.17%
2,233,416
+655,489
+42% +$16M
EDIT icon
11
Editas Medicine
EDIT
$457M
$52.5M 2.07%
1,709,400
– –
DBVT
12
DBV Technologies
DBVT
$870M
$51.8M 2.04%
210,518
+144,928
+221% +$41.9M
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$51.7M 2.04%
1,522,566
+450,237
+42% +$12.8M
PODD icon
14
Insulet
PODD
$11.4B
$48.7M 1.92%
705,573
+208,573
+42% +$13.7M
XENT
15
DELISTED
Intersect ENT, Inc
XENT
$47.6M 1.87%
1,468,341
+258,341
+21% +$7.75M
GWPH
16
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$44.8M 1.76%
339,180
-23,544
-6% -$2.77M
MOH icon
17
Molina Healthcare
MOH
$11.7B
$43.6M 1.71%
568,000
+310,000
+120% +$22.4M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$42.1M 1.66%
1,000,680
-364,359
-27% -$14M
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$37.2M 1.46%
1,190,516
-334,894
-22% -$9.19M
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
$35.8M 1.41%
+1,000,000
New +$28.7M
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.36B
$35.4M 1.39%
7,213,393
+2,237,942
+45% +$10.8M
SEM
22
DELISTED
Select Medical
SEM
$32.8M 1.29%
3,448,448
+1,231,254
+56% +$11.8M
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
$32.4M 1.28%
3,955,494
+300,000
+8% +$2.81M
ASND icon
24
Ascendis Pharma A/S
ASND
$17.1B
$31.6M 1.24%
789,000
-61,000
-7% -$2.22M
DVA icon
25
DaVita
DVA
$15.2B
$30.7M 1.21%
+425,000
New +$26.2M
1
2 3 4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2017 Portfolio in Review

As of Q4 2017, Deerfield Management held 112 positions worth $2.54B, up 14% from $2.22B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $140M in Q4 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was NxStage Medical Inc., an estimated $43.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Revance Therapeutics, Inc. worth $35.8M.

  • Deerfield Management's largest Q4 2017 buy was Revance Therapeutics, Inc.: 1,000,000 shares worth $35.8M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, an estimated $105M increase.
  • Deerfield Management's biggest Q4 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $79.5M.
  • Deerfield Management fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $43.6M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.54B portfolio in Q4 2017.
  • Deerfield Management opened 21 new positions and closed 14 in Q4 2017.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.